The "Pharmerging Market Analysis By Product, By Region {Tier I (China), Tier II (India, Brazil, Russia, South Africa) Tier III (Argentina, Mexico, Poland, Turkey, Indonesia)}, And Segment Forecasts, 2014 - 2025" report has been added to ResearchAndMarkets.com's offering.
The global pharmerging market is expected to reach USD 2,231.9 billion by 2025
This market is expected to grow due to increasing geriatric population, increasing disease burden of chronic disorders and increasing healthcare expenditure.
According to the United Nations (UN), the number of people above the age of 60 years are estimated to be 901 million in 2015. This number is expected to increase to 1.4 billion by 2030 and 2.1 billion by 2050. The increasing geriatric population boosts the demand for better treatment options for chronic diseases such as hyperlipidemia, hypertension, cancer, dementia, congestive heart failure. According to a study conducted by Deloitte in 2011, the geriatric population accounts for almost 23.0-40.0% of the prescription drug market, and 40.0-50.0% of the OTC drug market.
Another driving factor for the pharmerging market is increasing healthcare expenditure. The global healthcare spending is expected to increase from USD 7.83 trillion in 2013 to USD 18.28 trillion in 2040. It has also been estimated that there will an increase of 3.4%, 3.0%, 2.4% in healthcare expenditure in upper middle-level income countries, lower middle-level income countries and in low-income level countries respectively.
The increasing disease burden of chronic diseases in developing countries is boosting the growth in the market. According to the Global Health Observatory data, in 2015, 70.0% of the deaths were due to non-communicable diseases (NCD). The major NCDs are cardiovascular diseases (CVD) which caused 45.0% of all NCD deaths, cancer which caused 22.0% of all NCD deaths and chronic obstructive pulmonary disease (COPD) which causes 10.0% of all NCD deaths, and diabetes which caused 4.0% of all NCD deaths.
Key Topics Covered:
Chapter 1 Executive Summary
Chapter 2 Research Methodology
Chapter 3 Pharmerging Market Variables, Trends & Scope
Chapter 4 Pharmerging Market Regional Estimates & Trend Analysis, By Service
Chapter 5 Competitive Landscape
- Sanofi
- Pfizer Inc.
- AstraZeneca
- GlaxoSmithKline
- F.Hoffmann-La Roche Ltd
- GE Healthcare
- Eli Lilly
- Medtronic
- Johnson and Johnson
- Abbott
For more information about this report visit https://www.researchandmarkets.com/research/z7hp84/global?w=4
View source version on businesswire.com: http://www.businesswire.com/news/home/20180129005776/en/